Huminsulin 30/70 Suspension for Injection 100 IU/ml is a premixed insulin formulation containing 70% insulin isophane (NPH insulin) and 30% human insulin. This combination provides both intermediate-acting and short-acting insulin components, facilitating improved glycemic control in patients with diabetes mellitus. The insulin isophane component offers a prolonged onset and duration of action, typically providing basal insulin coverage, while the human insulin fraction addresses postprandial glucose excursions with a more rapid onset. Huminsulin 30/70 is indicated for the treatment of type 1 and type 2 diabetes when diet, exercise, and oral hypoglycemic agents alone do not achieve adequate glycemic control. It is administered subcutaneously, with dosage individualized based on patient needs, blood glucose monitoring, and glycemic targets. Proper resuspension of the suspension by gentle mixing prior to injection is essential to ensure consistent dosing. Patients should be educated on injection technique, timing relative to meals, and recognition of hypoglycemia symptoms. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary. Huminsulin 30/70 should not be administered intravenously. As with all insulin therapies, close monitoring of blood glucose levels is critical to optimize therapy and minimize adverse effects.